|
On (b)(6) 2014, this patient underwent endovascular treatment of an abdominal aortic aneurysm measuring 53mm in diameter and was implanted with gore® excluder® aaa endoprosthesis featuring c3® deployment system.The patient tolerated the procedure and was discharged from the hospital on (b)(6) 2014.On (b)(6) 2014, follow-up computed tomography determined the maximum diameter of the aneurysm measured 55mm.On (b)(6) 2024, the patient was reported to have a type ii endoleak related to the aortic device or procedure.Follow-up ultrasound determined the maximum diameter of the aneurysm measured 68 mm.The cause is believed to have been due to device migration, coupled with the patient being reported to have a short aortic neck.On (b)(6) 2024, the patient is scheduled to undergo reintervention wherein ir embolization of the type ii endoleak with anesthesia is to be performed.
|
|
The instructions for use (ifu) for the gore® excluder® aaa endoprosthesis states; adverse events that may occur and / or require intervention include but are not limited to: endoleak, aneurysm enlargement.W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute a legal admission by anyone that the product described in this report has any defects or has malfunctioned, as defined from a legal standpoint.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
|